BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AllerT: Additional Phase I/IIa data

Additional data from the double-blind, placebo-controlled, Swiss Phase I/IIa AN003 trial in 18 evaluable patients showed that AllerT significantly increased mean allergen-specific IgG4 levels from baseline to 16-18 months after the last injection (2 months after the 2010...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >